NO20072235L - HCV-hemmende bicykliske pyrimidiner - Google Patents

HCV-hemmende bicykliske pyrimidiner

Info

Publication number
NO20072235L
NO20072235L NO20072235A NO20072235A NO20072235L NO 20072235 L NO20072235 L NO 20072235L NO 20072235 A NO20072235 A NO 20072235A NO 20072235 A NO20072235 A NO 20072235A NO 20072235 L NO20072235 L NO 20072235L
Authority
NO
Norway
Prior art keywords
present
hcv
bicyclic pyrimidines
relates
pyrimidines
Prior art date
Application number
NO20072235A
Other languages
English (en)
Inventor
Dominique Louis Nest Surleraux
Pierre Jean-Marie Raboisson
Kenneth Alan Simmen
Tse-I Lin
Oliver Lenz
Original Assignee
Tibotech Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35448001&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072235(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotech Pharmaceuticals Ltd filed Critical Tibotech Pharmaceuticals Ltd
Publication of NO20072235L publication Critical patent/NO20072235L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Foreliggende oppfinnelse vedrører anvendelsen av bicykliske pyrimidiner som inhibitorer av HCV-replikasjon samt deres anvendelse i farmasøytiske sammensetninger rettet mot å behandle eller bekjempe HCV-infeksjoner. I tillegg vedrører foreliggende oppfinnelse fremgangsmåter for fremstilling av slike farmasøytiske sammensetninger. Foreliggende oppfinnelse vedrører også kombinasjoner av foreliggende bicykliske pyrimidiner med andre anti-HCV-midler. ?? ?? ?? ??
NO20072235A 2004-09-30 2007-04-30 HCV-hemmende bicykliske pyrimidiner NO20072235L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04104815 2004-09-30
EP05102810 2005-04-08
PCT/EP2005/054912 WO2006035061A1 (en) 2004-09-30 2005-09-29 Hcv inhibiting bi-cyclic pyrimidines

Publications (1)

Publication Number Publication Date
NO20072235L true NO20072235L (no) 2007-06-28

Family

ID=35448001

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072235A NO20072235L (no) 2004-09-30 2007-04-30 HCV-hemmende bicykliske pyrimidiner

Country Status (15)

Country Link
US (1) US7977342B2 (no)
EP (1) EP1799218A1 (no)
JP (1) JP5046942B2 (no)
KR (1) KR20070058602A (no)
CN (1) CN100594903C (no)
AP (1) AP2007003923A0 (no)
AR (1) AR052771A1 (no)
AU (1) AU2005288858B2 (no)
BR (1) BRPI0516751A (no)
CA (1) CA2577745C (no)
IL (1) IL181226A (no)
NO (1) NO20072235L (no)
RU (1) RU2380101C2 (no)
TW (1) TW200626157A (no)
WO (1) WO2006035061A1 (no)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006040966A1 (ja) * 2004-10-08 2006-04-20 Astellas Pharma Inc. 芳香環縮合ピリミジン誘導体
TW200621257A (en) * 2004-10-20 2006-07-01 Astellas Pharma Inc Pyrimidine derivative fused with nonaromatic ring
KR20070118068A (ko) * 2004-11-23 2007-12-13 레디 유에스 테라퓨틱스 인코포레이티드 신규의 이원 헤테로고리 화합물, 그 제조방법 및 이들을포함하는 조성물
US7402596B2 (en) 2005-03-24 2008-07-22 Renovis, Inc. Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
BRPI0609650A2 (pt) * 2005-03-25 2010-04-20 Tibotec Pharm Ltd inibidores heterobicìlicos de hvc
JP5198256B2 (ja) 2005-05-04 2013-05-15 エボテク エージー 縮合複素環式化合物、並びにそれらの組成物及び使用
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
WO2007011759A2 (en) * 2005-07-15 2007-01-25 Kalypsys, Inc. Inhibitors of mitotic kinesin
WO2007076035A2 (en) 2005-12-21 2007-07-05 Abbott Laboratories Anti-viral compounds
ATE541844T1 (de) 2005-12-21 2012-02-15 Abbott Lab Antivirale verbindungen
WO2007081517A2 (en) * 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
CN101443334A (zh) * 2005-12-21 2009-05-27 艾博特公司 抗病毒化合物
DE102006029074A1 (de) 2006-06-22 2007-12-27 Friedrich-Schiller-Universität Jena 4-Amino-3-arylamino-6-arylpyrazolo[3,4-d]pyrimidin-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung als antivirale Wirkstoffe
WO2008021456A2 (en) * 2006-08-16 2008-02-21 Cytovia, Inc. N-aryl-5,7-dihydrofuro[3,4-d]pyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab ANTIVIRAL COMPOUNDS
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
WO2008131050A1 (en) * 2007-04-18 2008-10-30 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
JP5608099B2 (ja) * 2008-01-30 2014-10-15 ジェネンテック， インコーポレイテッド ピラゾロピリミジンｐｉ３ｋ阻害剤化合物および使用方法
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2010011620A1 (en) * 2008-07-21 2010-01-28 Wyeth 4-phenoxy-6-aryl-1h-pyrazolo[3,4-d]pyrimidine and n-aryl-6-aryl-1h-pyrazolo[3,4-d]pyrimidin-4-amine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
US8163763B2 (en) 2008-07-31 2012-04-24 Genentech, Inc. Pyrimidine compounds, compositions and methods of use
PE20100362A1 (es) * 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
US8653098B2 (en) 2008-11-20 2014-02-18 Genentech, Inc. Pyrazolopyridine PI3K inhibitor compounds and methods of use
UA108193C2 (uk) 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
WO2010071885A1 (en) 2008-12-19 2010-06-24 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
AR074897A1 (es) 2008-12-23 2011-02-23 Pharmasset Inc Fosforamidatos de nucleosidos
MX2011006890A (es) 2008-12-23 2011-07-20 Pharmasset Inc Analogos de nucleosidos.
CL2009002206A1 (es) 2008-12-23 2011-08-26 Gilead Pharmasset Llc Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
TWI576352B (zh) 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
WO2011058027A2 (en) 2009-11-12 2011-05-19 F. Hoffmann-La Roche Ag N-9-substituted purine compounds, compositions and methods of use
ES2567168T3 (es) 2009-11-12 2016-04-20 F. Hoffmann-La Roche Ag Compuestos purina y pirazolopirimidina N7-sustituidos, composiciones y métodos de utilización
AP2012006535A0 (en) 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
PL3290428T3 (pl) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
TW201136945A (en) 2010-03-31 2011-11-01 Pharmasset Inc Purine nucleoside phosphoramidate
ES2716158T3 (es) 2010-11-30 2019-06-10 Gilead Pharmasset Llc 2'-spiro-nucleótidos para el tratamiento de hepatitis C
US8846656B2 (en) 2011-07-22 2014-09-30 Novartis Ag Tetrahydropyrido-pyridine and tetrahydropyrido-pyrimidine compounds and use thereof as C5a receptor modulators
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
SG11201406997WA (en) * 2012-05-04 2014-11-27 Merck Patent Gmbh Pyrrolotriazinone derivatives
JPWO2014034898A1 (ja) 2012-08-30 2016-08-08 日本新薬株式会社 ピリジン誘導体及び医薬
HK1206728A1 (en) * 2012-09-17 2016-01-15 AbbVie Deutschland GmbH & Co. KG Novel inhibitor compounds of phosphodiesterase type 10a
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
MX2015009678A (es) * 2013-02-04 2015-11-25 Gruenenthal Gmbh Compuestos de pirimidina condensada sustituida con amino en la posicion 4 como inhibidores de fosfodiesterasa 4 (pde4).
TW201446767A (zh) 2013-02-15 2014-12-16 Almirall Sa 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
US9050345B2 (en) 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9879014B2 (en) * 2013-07-12 2018-01-30 Kyoto University Method for screening substance capable of inhibiting abnormal splicing causative of onset or progress of disease
EA201690473A1 (ru) 2013-08-27 2017-03-31 ГАЙЛИД ФАРМАССЕТ ЭлЭлСи Комбинированный состав двух противовирусных соединений
PL3089971T3 (pl) 2014-01-01 2021-01-25 Medivation Technologies Llc Związki i sposoby ich zastosowania
WO2016067099A1 (en) 2014-10-29 2016-05-06 King Abdullah University Of Science And Technology 3-alkyl pyridinium compound from red sea sponge with potent antiviral activity
EP3240537B1 (en) * 2014-12-30 2020-09-09 F. Hoffmann-La Roche AG Novel tetrahydropyridopyrimidines and tetrahydropyridopyridines for the treatment and prophylaxis of hepatitis b virus infection
CN108349976A (zh) * 2015-08-25 2018-07-31 百时美施贵宝公司 TGFβ受体拮抗剂
DK3356345T3 (da) 2015-09-30 2024-02-12 Max Planck Gesellschaft Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
EA201892200A1 (ru) * 2016-04-01 2019-03-29 Янссен Фармасьютикалз, Инк. Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
EP3478680B1 (en) * 2016-06-29 2020-04-22 H. Hoffnabb-La Roche Ag Novel tetrahydropyridopyrimidines for the treatment and prophylaxis of hbv infection
EP3911649A1 (en) 2019-01-17 2021-11-24 F. Hoffmann-La Roche AG A process for the preparation of tetrahydropyridopyrimidines
CN111825674A (zh) * 2019-04-22 2020-10-27 上海仕谱生物科技有限公司 嘧啶并五元杂环类化合物及其作为突变型idh2抑制剂的用途
RU2746423C2 (ru) * 2019-09-02 2021-04-13 Общество с ограниченной ответственностью "Научно-исследовательский институт ХимРар" (ООО "НИИ ХимРар") Ингибитор вируса гепатита В (ВГВ)
CN111548349A (zh) * 2020-05-13 2020-08-18 厦门云凡医药科技有限公司 一种ret激酶抑制剂中间体及其制备方法
CN112724157B (zh) * 2021-01-23 2022-04-19 中国科学院新疆理化技术研究所 二氢噁唑并[5,4-d]吡咯并[1,2-a]嘧啶-9(5H)-酮类衍生物及用途
CN116621843B (zh) * 2022-06-13 2024-05-24 四川大学华西医院 一种dna甲基转移酶1抑制剂及其制备方法和用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2295387A (en) * 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
RU2123328C1 (ru) * 1996-04-19 1998-12-20 Государственный научный центр вирусологии и биотехнологии "Вектор" Липосомальное противовирусное лекарственное средство для перорального применения
US6184226B1 (en) 1998-08-28 2001-02-06 Scios Inc. Quinazoline derivatives as inhibitors of P-38 α
CA2396693A1 (en) 1999-12-28 2001-07-05 Stephen T. Wrobleski Cytokine, especially tnf-alpha, inhibitors
AU2001290912A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HN2002000067A (es) 2001-03-23 2003-10-24 Bayer Healthcare Llc Inhibidores de la rho - quinasa.
US20040009981A1 (en) 2002-03-15 2004-01-15 David Bebbington Compositions useful as inhibitors of protein kinases
WO2003077921A1 (en) 2002-03-15 2003-09-25 Vertex Pharmaceuticals, Inc. Azinylaminoazoles as inhibitors of protein kinases
US6846928B2 (en) 2002-03-15 2005-01-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of protein kinases
AU2003225800A1 (en) 2002-03-15 2003-09-29 Hayley Binch Azolylaminoazine as inhibitors of protein kinases
AU2003229305A1 (en) 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
US20040127575A1 (en) 2002-11-22 2004-07-01 Feng Ying Method for counteracting a pathologic change in the beta-adrenergic pathway
WO2004047818A2 (en) 2002-11-22 2004-06-10 Scios, Inc. USE OF TFG-β INHIBITORSTO COUNTERACT PATHOLOGIC CHANGES IN THE LEVEL OR FUNCTION OF STEROID/THYROID RECEPTORS
WO2004065392A1 (en) * 2003-01-24 2004-08-05 Smithkline Beecham Corporation Condensed pyridines and pyrimidines and their use as alk-5 receptor ligands
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
EP1608631A4 (en) * 2003-03-28 2008-08-20 Scios Inc BICYCLIC PYRIMIDININHIBITORS OF TGF BETA
US7232824B2 (en) 2003-09-30 2007-06-19 Scios, Inc. Quinazoline derivatives as medicaments
BRPI0609650A2 (pt) 2005-03-25 2010-04-20 Tibotec Pharm Ltd inibidores heterobicìlicos de hvc
CN101189234B (zh) 2005-03-25 2011-08-17 泰博特克药品有限公司 Hcv的杂二环抑制剂
AR056347A1 (es) 2005-05-12 2007-10-03 Tibotec Pharm Ltd Uso de compuestos de pteridina para fabricar medicamentos y composiciones farmaceuticas
AR054122A1 (es) 2005-05-12 2007-06-06 Tibotec Pharm Ltd Pirido[2,3-d]pirimidas utiles como inhibidores de hcv, y metodos para la preparacion de las mismas

Also Published As

Publication number Publication date
KR20070058602A (ko) 2007-06-08
CN101031304A (zh) 2007-09-05
RU2007116176A (ru) 2008-11-10
AU2005288858B2 (en) 2011-04-21
AR052771A1 (es) 2007-04-04
JP5046942B2 (ja) 2012-10-10
TW200626157A (en) 2006-08-01
AP2007003923A0 (en) 2007-02-28
WO2006035061A1 (en) 2006-04-06
BRPI0516751A (pt) 2008-09-16
CA2577745A1 (en) 2006-04-06
CA2577745C (en) 2012-11-27
EP1799218A1 (en) 2007-06-27
IL181226A0 (en) 2007-07-04
US7977342B2 (en) 2011-07-12
JP2008514678A (ja) 2008-05-08
AU2005288858A1 (en) 2006-04-06
US20070155716A1 (en) 2007-07-05
CN100594903C (zh) 2010-03-24
RU2380101C2 (ru) 2010-01-27
IL181226A (en) 2015-03-31

Similar Documents

Publication Publication Date Title
TW200626157A (en) HCV inhibiting bi-cyclic pyrimidines
NO20081628L (no) Benzodiazepiner som HCV-inhibitorer
TW200716631A (en) Pyrido[2,3-d]pyrimidines useful as HCV inhibitors, and methods for the preparation thereof
EA200800178A1 (ru) Ингибиторы вируса гепатита с (hcv)
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
EA200970805A1 (ru) Ингибиторы серинпротеаз для лечения hcv инфекций
DK2203430T3 (da) N-phenyl-dioxo-hydropyrimidiner anvendelige som inhibitorer for hepatitis C virus (HCV)
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
DE602006004844D1 (de) Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
ATE474835T1 (de) Als inhibitoren von proteinkinasen geeignete aminopyrimidine
NO20061479L (no) Anvendelse av modifiserte cyklosporiner for behandling av HCV-forstyrrelser
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
NO20080879L (no) HCV-NS3-proteaseinhibitorer
TW200639169A (en) Bicyclic heteroaryl derivatives for treating viruses
EA200901241A1 (ru) Соединения для лечения гепатита с
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
NO20092130L (no) Tricykliske heteroarylforbindelser anvendelige som inhibitorer of januskinase
WO2008057208A3 (en) Hcv ns3 protease inhibitors
WO2008051514A3 (en) Hcv ns3 protease inhibitors
WO2008051475A3 (en) Hcv ns3 protease inhibitors
EA200802118A1 (ru) Обладающие ингибирующей активностью в отношении mnk1/mnk2 тиенопиримидины, предназначенные для применения в фармацевтических композициях
DE602006021776D1 (de) Als kinaseinhibitoren geeignete aminopyrimidine
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application